Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PM8002 + FOLFOX
- Development stage
- Unknown
- Lead developer
- BioNTech
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Nucleic Acid-Directed Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Intravenous
01
Overview
PM8002 + FOLFOX is a combination therapy investigated primarily for the first-line treatment of hepatocellular carcinoma (HCC). **PM8002** is a bispecific antibody targeting both **PD-L1 (programmed death-ligand 1)** and **VEGF (vascular endothelial growth factor)**. This immunotherapy is designed to both inhibit immune checkpoint-mediated cancer cell immune evasion and suppress angiogenesis in tumors. **FOLFOX** is a standard chemotherapy regimen consisting of **oxaliplatin** (a platinum-based DNA cross-linker), **leucovorin (folinic acid)** (a chemopotentiator), and **fluorouracil (5-FU)** (a pyrimidine analog antimetabolite). The FOLFOX regimen acts primarily by causing DNA damage and inhibiting DNA synthesis in rapidly proliferating cancer cells. The combination aims to enhance anti-tumor immune responses and direct cytotoxic effects. The developer of PM8002 is **Biotheus Inc.**
- Other names
- PM8002 plus FOLFOXPM-8002 plus FOLFOXPM 8002 plus FOLFOXPM8002+FOLFOX-4
02
Targets
TS (Thymidylate synthase)VEGFA (Vascular endothelial growth factor A)CD274 (Programmed cell death protein 1 ligand 1)DNA
Beyond the preview
Go deeper on PM8002 + FOLFOX.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PM8002 + FOLFOX.